Alvotech (ALVO) Stock Price, News & Analysis

Company Overview

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara). The company’s lead candidate, AVT02 (a biosimilar to adalimumab), is being developed in collaboration with Teva Pharmaceuticals and has received marketing approval in several regions. Additional programs in late‐stage development aim to replicate therapies used across autoimmune disorders and cancer treatment, underscoring Alvotech’s focus on high‐value therapeutic areas.

Headquartered in Reykjavík, Iceland, Alvotech operates state‐of‐the‐art facilities that integrate research, development and large‐scale manufacturing under one roof. The company has also established regulatory and commercial partnerships to support product launches in key markets, including the United States, Europe and select Asia‐Pacific territories. This global footprint enables Alvotech to align its clinical development plans with regional regulatory requirements while optimizing supply chain logistics for commercial distribution.

Alvotech’s leadership team is led by Founder and Executive Chairman Robert Wessman, a biopharmaceutical entrepreneur with decades of industry experience. Under his guidance, the company has expanded its scientific capabilities and forged strategic alliances to advance its biosimilar portfolio. Supported by a management team with expertise in biologics development, regulatory affairs and global commercialization, Alvotech is positioned to play a significant role in increasing patient access to affordable biologic therapies.

Key Stats

• Today's Range: $3.17 to $3.26
• 50-Day Range: $3.11 to $4.16
• 52-Week Range: $3.03 to $11.85
• Volume: 156,087 shs
• Average Volume: 490,926 shs
• Market Capitalization: $967.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.60
• Consensus Rating: Hold

Alvotech Stock Analysis - MarketRank™

Alvotech scored higher than 67% of companies evaluated by MarketBeat, and ranked 153rd out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Alvotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 2 sell ratings.

Upside Potential

Alvotech has a consensus price target of $7.60, representing about 137.5% upside from its current price of $3.20.

Amount of Analyst Coverage

Alvotech has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 2,000.00%

Earnings Growth

Earnings for Alvotech are expected to grow by 2,000.00% in the coming year, from $0.01 to $0.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alvotech is -12.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alvotech is -12.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.90% of the float of Alvotech has been sold short.

Short Interest Ratio / Days to Cover

Alvotech has a short interest ratio ("days to cover") of 7.58.

Change versus previous month

Short interest in Alvotech has recently decreased by 9.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alvotech does not currently pay a dividend.

Dividend Growth

Alvotech does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.33

News Sentiment

Alvotech has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Alvotech this week, compared to 8 articles on an average week.

Search Interest

4 people have searched for ALVO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alvotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.46% of the stock of Alvotech is held by insiders.

Percentage Held by Institutions

Alvotech has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALVO
• Previous Symbol: NYSE:ALVO
• CIK: 1898416
• Web: www.alvotech.com
• Phone: 354-422-4500
• Fax: N/A
• Employees: 1,460
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Alvotech: $7.60
• High Price Target: $10.00
• Low Price Target: $4.00
• Potential Upside/Downside: +137.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.10
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 320.50
• P/E Growth: N/A
• Net Income: $27.92 million
• Net Margins: -14.36%
• Pretax Margin: 23.25%
• Return on Equity: -11.92%
• Return on Assets: -7.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.89
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: $588.90 million
• Price / Sales: 1.64
• Cash Flow: $0.20 per share
• Price / Cash Flow: 16.38
• Book Value: ($0.94) per share
• Price / Book: -3.41

Miscellaneous

• Outstanding Shares: 301,810,000
• Free Float: 300,418,000
• Market Cap: $967.30 million
• Optionable: Not Optionable
• Beta: 0.21